TMLI and Alemtuzumab for Treatment of Sickle Cell Disease
Clinical trial NCT05384756 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05384756
- Sponsor
- City of Hope Medical Center
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-07-13
- Primary completion
- 2026-12-01
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.